ArticleParasites & vectors2019
A combination of metabolic resistance and high frequency of the 1014F kdr mutation is driving pyrethroid resistance in Anopheles coluzzii population from Guinea savanna of Cameroon.
Article in Parasites & vectors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Performance assessment of Bayesian meta-analytic predictive model on kdr mutation in insecticide-resistant malarial vectors in sub-Saharan Africa.Malaria journal · 2025Pooled it
- Physicians' knowledge of, and willingness to encourage caregivers to partake in the RTS S/AS01 and R21 matrix M malaria vaccines roll out - a national survey in Nigeria.BMC infectious diseases · 2025Article
- Characterizing the escalation of pyrethroid resistance and its impact on bed nets efficacy alongside molecular basis in Anopheles funestus from Cameroon.Malaria journal · 2025Article
- Susceptibility profile of Anopheles and target site resistance mechanism against organophosphates in Cameroon.PloS one · 2025Article
- Exploring the molecular mechanisms of increased intensity of pyrethroid resistance in Central African population of a major malaria vectorEvolutionary applications · 2024Article
- Baseline susceptibility of Anopheles gambiae to clothianidin in northern Ghana.Malaria journal · 2024Article
- Pyrethroid resistance and gene expression profile of a new resistantWellcome open research · 2024Article
- High efficacy of chlorfenapyr-based net InterceptorInfectious diseases of poverty · 2023Article
- Molecular drivers of insecticide resistance in the Sahelo-Sudanian populations of a major malaria vector Anopheles coluzzii.BMC biology · 2023Article
- The duplicated P450s CYP6P9a/b drive carbamates and pyrethroids cross-resistance in the major African malaria vector Anopheles funestus.PLoS genetics · 2023Article
- Malaria among children under 10 years in 4 endemic health areas in Kisantu Health Zone: epidemiology and transmission.Malaria journal · 2023Article
- Article
- Article
- Insecticide Resistance Profile and Mechanisms inInsects · 2022Article
- Seasonal variation of microbiota composition in Anopheles gambiae and Anopheles coluzzii in two different eco-geographical localities in Cameroon.Medical and veterinary entomology · 2022Article
- Bendiocarb and Malathion Resistance in Two Major Malaria Vector Populations in Cameroon Is Associated with High Frequency of the G119S Mutation (Ace-1) and Overexpression of Detoxification Genes.Pathogens (Basel, Switzerland) · 2022Article
- Molecular Drivers of Multiple and Elevated Resistance to Insecticides in a Population of the Malaria VectorGenes · 2022Article
- Distribution of acetylcholinesterase (Ace-1Parasites & vectors · 2022Article
- Transposable element variants and their potential adaptive impact in urban populations of the malaria vectorGenome research · 2022Article
- Molecular detection and maternal transmission of a bacterial symbiont Asaia species in field-caught Anopheles mosquitoes from Cameroon.Parasites & vectors · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundThe scale-up in the distribution of long-lasting insecticidal nets (LLINs) and indoor residual spraying has significantly reduced malaria burden and mortality. However, insecticide resistance, among other factors, is responsible for a recent rebound in malaria transmission in 2015-2016, threatening the progress so far made. As a contribution towards understanding patterns of resistance and its mechanism in the field we characterized a population of Anopheles gambiae (s.l.) from Gounougou, a Guinea savanna of north/central Cameroon.
resultsIndoor collection conducted in September 2017 identified Anopheles coluzzii and Anopheles arabiensis as the unique Anopheles vector species, with abundances of 83 and 17%, respectively. Analysis of infection with TaqMan assays using heads/thoraces of indoor collected females of An. coluzzii revealed a low Plasmodium falciparum parasite rate of 4.7%. Bioassays conducted with female An. coluzzii revealed extreme resistance, with low mortalities of only 3.75 ± 1.25%, 3.03 ± 1.59% and 1.45 ± 1.45%, respectively, for permethrin, deltamethrin and DDT. In contrast, high susceptibility was obtained with the organophosphates and carbamates, with mortalities in the range of 98-100%. Synergist assays with piperonyl butoxide (PBO) recovered some susceptibility with increased mortality for permethrin to 14.88 ± 8.74%, and for deltamethrin to 32.50 ± 10.51% (~27-fold increase compared to mortalities with deltamethrin alone, χ
conclusionsThis finding of high pyrethroid and DDT resistance in An. coluzzii from north-central Cameroon is a major obstacle to malaria control using pyrethroid bednets and indoor residual spraying with DDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.